A new clinical study is introducing a six-monthly injectable PrEP named Lenacapivir for sexually active women in various parts of England, including Birmingham and London. This trial aims to evaluate the effectiveness of the injectable as an alternative to the daily tablet currently available. Notably, women who have sex with men represent the highest percentage of new HIV diagnoses in England. Dr. Steve Taylor, associated with the research, highlights the potential to improve HIV prevention efforts significantly, particularly for women who are less likely to use current PrEP options.
Women who have sex with men now account for the highest proportion of new HIV diagnoses in England, making this injectable PrEP option crucial for prevention.
Dr. Steve Taylor emphasizes the potential of injectable PrEP technologies to transform HIV prevention efforts in the UK and beyond, especially for women.
The study aims to test if the new injections can offer additional benefits over existing daily tablets and serve as a more acceptable option for women.
With only 4% of PrEP prescriptions currently for women in the UK, this clinical trial seeks to address unmet needs in HIV prevention among women.
Collection
[
|
...
]